Search research articles
Contact Us
Filters
Showing results (21-30 of 113) with videos related to
Page
of 12
Sort By:
Plos One
|
May 13, 2016
Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes
Kanwal Raghav, Hemendra Mhadgut, Jennifer L McQuade, et al.
The Oncologist
|
February 1, 2021
Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait
Ryan W Huey, Brandon G Smaglo, Jeannelyn S Estrella, et al.
Abdominal Imaging
|
April 24, 2015
Analysis of free-form radiology dictations for completeness and clarity for pancreatic cancer staging
Leonardo P Marcal, Patricia S Fox, Douglas B Evans, et al.
Investigational New Drugs
|
September 30, 2005
Phase I trial of oral talactoferrin alfa in refractory solid tumors
Teresa G Hayes, Gerald F Falchook, Gauri R Varadhachary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
Michael J Overman, Gauri R Varadhachary, Scott Kopetz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 7, 2011
Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis
Patrick Kelly, Prajnan Das, Gauri R Varadhachary, et al.
Annals of Surgical Oncology
|
September 12, 2012
Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement
Daniel E Abbott, Ryan P Merkow, Scott B Cantor, et al.
Journal of Hematology & Oncology
|
May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Reham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.
Cancer
|
November 19, 2016
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study
Pat Gulhati, Kanwal Raghav, Rachna T Shroff, et al.
Human Pathology
|
April 22, 2014
Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma
Rongjun Guo, Michael Overman, Deyali Chatterjee, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 113) with videos related to
Sort By:
Page
of 12
Plos One
|
May 13, 2016
Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes
Kanwal Raghav, Hemendra Mhadgut, Jennifer L McQuade, et al.
The Oncologist
|
February 1, 2021
Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait
Ryan W Huey, Brandon G Smaglo, Jeannelyn S Estrella, et al.
Abdominal Imaging
|
April 24, 2015
Analysis of free-form radiology dictations for completeness and clarity for pancreatic cancer staging
Leonardo P Marcal, Patricia S Fox, Douglas B Evans, et al.
Investigational New Drugs
|
September 30, 2005
Phase I trial of oral talactoferrin alfa in refractory solid tumors
Teresa G Hayes, Gerald F Falchook, Gauri R Varadhachary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
Michael J Overman, Gauri R Varadhachary, Scott Kopetz, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 7, 2011
Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis
Patrick Kelly, Prajnan Das, Gauri R Varadhachary, et al.
Annals of Surgical Oncology
|
September 12, 2012
Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement
Daniel E Abbott, Ryan P Merkow, Scott B Cantor, et al.
Journal of Hematology & Oncology
|
May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Reham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.
Cancer
|
November 19, 2016
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study
Pat Gulhati, Kanwal Raghav, Rachna T Shroff, et al.
Human Pathology
|
April 22, 2014
Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma
Rongjun Guo, Michael Overman, Deyali Chatterjee, et al.
Page
of 12